HiFiBiO

company

About

HiFiBiO provides proprietary single cell technologies for applications in drug and biomarker discovery and development.

  • 101 - 250

Details

Last Funding Type
Series D
Last Funding Money Raised
$75M
Industries
Biopharma,Biotechnology,Pharmaceutical,Therapeutics
Founded date
Jan 1, 2013
Number Of Employee
101 - 250
Operating Status
Active

HiFiBiO is a biotherapeutics company that mobilizes the human immune system to combat disease. It commercializes proprietary single-cell technologies for applications in drug and biomarker discovery and development. It also aspires to benefit patients through open-innovation partnerships with industry and academia. HiFiBiO integrates deep-rooted biological expertise with its comprehensive single-cell profiling technologies to discover and accelerate a pipeline of antibody drugs to treat cancer and autoimmune disorders.

The company was founded in 2013 and is headquartered in Paris, Ille-de-France.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$142M
HiFiBiO has raised a total of $142M in funding over 2 rounds. Their latest funding was raised on Jun 14, 2021 from a Series D round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jun 14, 2021 Series D $75M 2 Detail
Aug 28, 2019 Series C $67M 2 Detail

Investors

Number of Lead Investors
Number of Investors
4
HiFiBiO is funded by 4 investors. Hong Kong Science and Technology Parks Corporation (HKSTP) and Further are the most recent investors.
Investor Name Lead Investor Funding Round
Hong Kong Science and Technology Parks Corporation (HKSTP) Series D
Further Series D
Kite Pharma Series C
VI Ventures Series C